JP2022528010A - メープルシロップ尿症（ｍｓｕｄ）のａａｖ媒介遺伝子治療 - Google Patents

メープルシロップ尿症（ｍｓｕｄ）のａａｖ媒介遺伝子治療 Download PDF

Info

Publication number
JP2022528010A
JP2022528010A JP2021560728A JP2021560728A JP2022528010A JP 2022528010 A JP2022528010 A JP 2022528010A JP 2021560728 A JP2021560728 A JP 2021560728A JP 2021560728 A JP2021560728 A JP 2021560728A JP 2022528010 A JP2022528010 A JP 2022528010A
Authority
JP
Japan
Prior art keywords
bckdha
endogenous
bckdhb
nucleic acid
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021560728A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022528010A5 (https=
Inventor
ガオ，グアンピン
ワン，ダン
ワン，ジアミン
ストラウス，ケビン，エー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clinic for Special Children
Original Assignee
Clinic for Special Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clinic for Special Children filed Critical Clinic for Special Children
Publication of JP2022528010A publication Critical patent/JP2022528010A/ja
Publication of JP2022528010A5 publication Critical patent/JP2022528010A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/04—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with a disulfide as acceptor (1.2.4)
    • C12Y102/04004—3-Methyl-2-oxobutanoate dehydrogenase (2-methylpropanoyl-transferring) (1.2.4.4), i.e. branched-chain-alpha-ketoacid dehydrogenase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021560728A 2019-04-12 2020-04-10 メープルシロップ尿症（ｍｓｕｄ）のａａｖ媒介遺伝子治療 Pending JP2022528010A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962833159P 2019-04-12 2019-04-12
US62/833,159 2019-04-12
US201962930687P 2019-11-05 2019-11-05
US62/930,687 2019-11-05
PCT/US2020/027622 WO2020210595A1 (en) 2019-04-12 2020-04-10 Aav-mediated gene therapy for maple syrup urine disease (msud)

Publications (2)

Publication Number Publication Date
JP2022528010A true JP2022528010A (ja) 2022-06-07
JP2022528010A5 JP2022528010A5 (https=) 2023-04-18

Family

ID=72752067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560728A Pending JP2022528010A (ja) 2019-04-12 2020-04-10 メープルシロップ尿症（ｍｓｕｄ）のａａｖ媒介遺伝子治療

Country Status (5)

Country Link
US (2) US12398378B2 (https=)
EP (1) EP3953484A4 (https=)
JP (1) JP2022528010A (https=)
CN (1) CN114008209A (https=)
WO (1) WO2020210595A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022528010A (ja) 2019-04-12 2022-06-07 ユニバーシティ オブ マサチューセッツ メープルシロップ尿症（ｍｓｕｄ）のａａｖ媒介遺伝子治療
WO2020257731A1 (en) * 2019-06-20 2020-12-24 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of maple syrup urine disease
JP2023515820A (ja) * 2020-02-28 2023-04-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル メープルシロップ尿症の遺伝子治療
US20240207370A1 (en) * 2021-04-26 2024-06-27 University Of Massachusetts Gene therapy for bcaa modulation in maple syrup urine disease (msud)
CN114561333B (zh) * 2022-02-23 2023-08-25 山东第一医科大学(山东省医学科学院) 一种转化支链氨基酸的工程菌及在制备治疗枫糖尿症产品中的应用
WO2025212609A1 (en) * 2024-04-02 2025-10-09 University Of Massachusetts Evolved nucleic acids encoding aspartoacylase proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019504888A (ja) * 2016-02-05 2019-02-21 エモリー ユニバーシティ 一本鎖アデノ随伴ウイルス９または自己相補型アデノ随伴ウイルス９の脳脊髄液への注射

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1331092A (zh) 2000-06-28 2002-01-16 上海博德基因开发有限公司 一种新的多肽——环指基因mid1蛋白10.56和编码这种多肽的多核苷酸
TR201908020T4 (tr) 2011-02-17 2019-06-21 Univ Pennsylvania Doku özgüllüğünü değiştirmek ve aav9-aracılı gen transferini geliştirmek için bileşimler ve yöntemler.
CN104099349B (zh) 2013-04-08 2018-07-24 深圳华大基因股份有限公司 枫糖尿病相关基因突变、其检测方法及其用途
CN107073051B (zh) 2014-10-21 2021-08-24 马萨诸塞大学 重组aav变体及其用途
JP2018509387A (ja) * 2015-01-21 2018-04-05 フェーズアールエックス インコーポレイテッド 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
WO2018016884A1 (ko) 2016-07-20 2018-01-25 주식회사 녹십자지놈 선천성 기능장애 진단용 조성물 및 이의 용도
WO2018185110A1 (en) 2017-04-03 2018-10-11 Fit Biotech Oy Novel expression vectors and uses thereof
WO2019071048A1 (en) * 2017-10-04 2019-04-11 The Broad Institute, Inc. SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITION
JP2022528010A (ja) 2019-04-12 2022-06-07 ユニバーシティ オブ マサチューセッツ メープルシロップ尿症（ｍｓｕｄ）のａａｖ媒介遺伝子治療
US20240207370A1 (en) 2021-04-26 2024-06-27 University Of Massachusetts Gene therapy for bcaa modulation in maple syrup urine disease (msud)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019504888A (ja) * 2016-02-05 2019-02-21 エモリー ユニバーシティ 一本鎖アデノ随伴ウイルス９または自己相補型アデノ随伴ウイルス９の脳脊髄液への注射

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOLECULAR THERAPY, vol. Vol 27, No 4S1, JPN6024013270, 22 April 2019 (2019-04-22), pages 238 - 239, ISSN: 0005298849 *

Also Published As

Publication number Publication date
US20220162570A1 (en) 2022-05-26
CN114008209A (zh) 2022-02-01
US12398378B2 (en) 2025-08-26
EP3953484A4 (en) 2023-04-12
EP3953484A1 (en) 2022-02-16
WO2020210595A9 (en) 2020-11-26
WO2020210595A1 (en) 2020-10-15
US20260062682A1 (en) 2026-03-05

Similar Documents

Publication Publication Date Title
US12467063B2 (en) Recombinant AAV vectors useful for reducing immunity against transgene products
US20230073187A1 (en) Prostate targeting adeno-associated virus serotype vectors
US20260062682A1 (en) Aav-mediated gene therapy for maple syrup urine disease (msud)
US20180214576A1 (en) Transgenic expression of dnasei in vivo delivered by an adeno-associated virus vector
JP7397488B2 (ja) Ｓｏｄ１二重発現ベクターおよびその使用
US12478692B2 (en) Gene therapy for spinal muscular atrophy
US20220202959A1 (en) Gene therapies for usher syndrome (ush2a)
US20260091132A1 (en) Gene therapies for usher syndrome (ush1b)
JP2021520811A (ja) ヘキソサミニダーゼアルファおよびベータサブユニットをコードしているバイシストロニックａａｖベクターならびにその使用
US20220403417A1 (en) Aav-based delivery of thymine kinase 2
US20240207370A1 (en) Gene therapy for bcaa modulation in maple syrup urine disease (msud)
US12497612B2 (en) Gene replacement therapy for FOXG1 syndrome
US12570997B2 (en) Factor H vectors and uses thereof
US20250135033A1 (en) Compositions and methods for treating sialidosis
WO2020210592A1 (en) Recombinant aav gene therapy for ngyl1 deficiency
US20250320503A1 (en) Aav vectors encoding sod1-targeting artificial mirnas (ami-rna)
US20240216534A1 (en) Direct raav-mediated in vivo gene editing of hematopoietic stem cells
CN118284698A (zh) 脊髓性肌萎缩症的基因疗法
WO2026090050A1 (en) Use of inverted terminal repeats (itrs) and itr-proximal region (iprs) in gene therapy vectors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230410

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240705

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240917